Evidence map›Paper›PMID 40606968›Full record

ReviewFrontiers in oncology2025

Age- and sex-specific impact on the progression of low-risk papillary thyroid carcinoma under active surveillance: a meta-analysis.

Yang Wang, Li Wang

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yang WangCenter for Endocrinology and Metabolic Diseases, The People's Hospital of Liaoning Province, Shenyang, China.
Li WangDepartment of Endocrine and Metabolism, Zhuhai People's Hospital (Zhuhai Hospital Affiliated with Jinan University), Zhuhai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The global incidence of papillary thyroid carcinoma (PTC) is increasing significantly. In response, active surveillance (AS) has been promoted for Low-risk PTC owing to the absence of associated mortality. However, the association between age, sex, and risk of tumor progression remains unclear. This study aimed to assess the age- and sex-specific Impact on the progression of low-risk PTC. Methods: PubMed and Web of Science Core Collection were searched for articles published up to 1 January 2024. Articles reporting patients with PTC undergoing AS were included. Studies involving patients who underwent total or partial thyroidectomy or radiofrequency ablation were excluded. Random- and fixed-effect models were applied to obtain pooled proportions and 95% CIs. Results: A total of 972 unique citations were screened and 39 full-text articles were reviewed, including eight cohorts. The mean or median age ranged from 41.5 to 53.1 years, with a predominant inclusion of female patients (76.39%-87.80%). The pooled risk ratio for tumor progression (a growth of 3 mm or more in maximal diameter or lymph node metastasis) in older adults (aged over 30-50 years) compared with younger individuals was 0.58 (95% CI, 0.47-0.71; 4,725 patients, six studies). However, for male patients, the pooled risk ratio for tumor progression compared with female individuals was 1.11 (95% CI, 0.64-1.93; 4,916 patients, six studies). Conclusion: This meta-analysis suggests that advanced age may be associated with a lower risk of progression of papillary thyroid microcarcinomas during active surveillance. No significant differences were observed between sexes.

Indexed as

active surveillanceagingmeta-analysisoncologic outcomespapillary thyroid cancer

Identifiers

PMID40606968
PMCPMC12213731

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.